Beta Bionics (BBNX) Stock Analysis & AI Equity Report

Medical - Equipment & Services USD Explore free reports

Beta Bionics (BBNX) overview

Beta Bionics (BBNX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 100m and operating profit of USD -71.7m; the year-end share price was 30.47 USD and market capitalisation was USD 1,352m. Beta Bionics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Beta Bionics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 288mFY 2025
Share price30.47 USDFY 2025 year end
RevenueUSD 100mFY 2025
Operating profitUSD -71.7mFY 2025
Net earningsUSD -73.2mFY 2025
Market capitalisationUSD 1,352mFY 2025 year end

About Beta Bionics

Beta Bionics develops and commercializes medical devices for people with diabetes who require insulin. Its product, the iLet Bionic Pancreas, uses adaptive closed-loop algorithms to support diabetes treatment and is cleared for people with Type 1 diabetes aged six and older. The company serves patients through commercialization of the device in the United States.

Generate the Beta Bionics report

Beta Bionics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Beta Bionics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Beta Bionics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.